This site is intended for
U.S.
Healthcare Professionals only.

SLAMF7

Signaling lymphocytic activation molecule family member 7 (SLAMF7), an activating receptor expressed on natural killer (NK) cells, can stimulate innate and adaptive immunity.

Expression and normal function

SLAMF7 is an activating receptor expressed on virtually all NK cells and other immune cell subsets¹

SLAMF7 is not expressed on solid tissues or hematopoietic stem cells²

Engagement of SLAMF7 activates NK cells, the rapid responders of the immune system and the body’s first line of defense against cancer^3,4
NK cells directly kill target cells, yet spare normal cells⁵

Collapse

Ongoing research

Continuous NK-cell activation through pathways like SLAMF7 may initiate the development of long-term immunity^6-8
Ongoing research aims to understand how NK-cell activation through SLAMF7 impacts long-term immunity

Diagram of how NK cell activation through SLAMF7 can impact innate and adaptive immunity

Collapse

How does SLAMF7 activate innate and adaptive immunity?

See the impact of SLAMF7 and continuous NK cell activation

Watch video

Get I-O Resources

Order or download
educational tools for your
patients and practice

See all resources

Clinical Trials

Learn more about
our
current clinical trials

Learn more

REFERENCES–SLAMF7

1. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol. 2001;167(10):5517-5521. 2. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008(9); 14:2775-2784. 3. Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10(3):297-305. 4. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230-252. 5. Frohn C, Höppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol. 2002; 119(3):660-664. 6. Liu C, Lou Y, Lizée G, et al. Plasmacytoid dendritic cells induce NK cell–dependent, tumor antigen–specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118(3):1165-1175. 7. Mocikat R, Braumüller H, Gumy A, et al. Natural killer cells activated by MHC class ILow targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19(4):561-569. 8. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-49.